

Appendix L: References – All Appendices

- 1 Schurch B, De S, Denys P, Chartier-Kastler E, Haab F, Everaert K et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. *Journal of Urology*. 2005; 174(1):196-200
- 2 Herschorn S, Gajewski J, Ethans K, Corcos J, Carlson K, Bailly G et al. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized double-blind trial. *Neurourology and Urodynamics*. 2009; 28(7):608-609
- 3 Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. *European Urology*. 2011; 60(4):742-750
- 4 Office for National Statistics. Life tables. 2011. [Last accessed: 1 April 2011]
- 5 Frankel HL, Coll JR, Charlifue SW, Whiteneck GG, Gardner BP, Jamous MA et al. Long-term survival in spinal cord injury: a fifty year investigation. *Spinal Cord*. 1998; 36(4):266-274
- 6 National Institute for Health and Clinical Excellence. The Guidelines Manual. London: National Institute for Health and Clinical Excellence; 2009. Available from: <http://www.nice.org.uk/aboutnice/howwework/developingniceclinicalguidelines/clinicalguidelin edevelopmentmethods/GuidelinesManual2009.jsp>
- 7 Koehler E, Brown E, Haneuse SJ. On the assessment of Monte Carlo error in simulation-based statistical analyses. *American Statistician*. 2009; 63(2):155-162
- 8 Pannek J, Gocking K, Bersch U. Long-term effects of repeated intradetrusor botulinum neurotoxin a injections on detrusor function in patients with neurogenic bladder dysfunction. *BJU International*. 2009; 104(9):1246-1250
- 9 Apostolidis A, Jacques TS, Freeman A, Kalsi V, Popat R, Gonzales G et al. Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity. *European Urology*. 2008; 53(6):1245-1253
- 10 Karsenty G, Reitz A, Lindemann G, Boy S, Schurch B. Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. *Urology*. 2006; 68(6):1193-1197
- 11 Reyblat P, Chan KG, Josephson DY, Stein JP, Freeman JA, Grossfeld GD et al. Comparison of extraperitoneal and intraperitoneal augmentation enterocystoplasty for neurogenic bladder in spinal cord injury patients. *World Journal of Urology*. 2009; 27(1):63-68
- 12 Metcalfe PD, Cain MP, Kaefer M, Gilley DA, Meldrum KK, Misseri R et al. What is the need for additional bladder surgery after bladder augmentation in childhood? *Journal of Urology*. 2006; 176(4 Pt 2):1801-1805
- 13 Game X, Castel-Lacanal E, Bentaleb Y, Thiry-Escudie I, de Boissezon X, Malavaud B et al. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity

- significantly decrease the incidence of symptomatic urinary tract infections. *European Urology*. 2008; 53(3):613-618
- 14 Hollingworth W, Campbell JD, Kowalski J, Ravelo A, Girod I, Briggs A et al. Exploring the impact of changes in neurogenic urinary incontinence frequency and condition-specific quality of life on preference-based outcomes. *Quality of Life Research*. 2010; 19(3):323-331
 - 15 Sullivan PW, Slejko JF, Sculpher MJ, Ghushchyan V. Catalogue of EQ-5D Scores for the United Kingdom. *Medical Decision Making*. 2011; 31(6):800-804
 - 16 Department of Health. NHS Reference Costs 2009-2010. London: Department of Health, 2011
 - 17 Joint Formulary Committee. British National Formulary (BNF). 60 edition. London: British Medical Association and The Royal Pharmaceutical Society of Great Britain; 2010. Available from: <http://www.bnf.org.uk>
 - 18 Department of Health. NHSCat. UK: Department of Health, 2010 Available from: <https://my.supplychain.nhs.uk/catalogue>
 - 19 Personal Social Services Research Unit and Curtis, L. Unit costs of health and social care. Canterbury: University of Kent, 2010
 - 20 Padmanabhan P, Scarpero H, Milam D, Dmochowski R, Penson D. Five-year cost analysis of intradetrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity. *World Journal of Urology*. 2011; 29(1):51-57